a medical device R&D manufacturer focusing on diseases of the digestive system and metabolic system

a medical device R&D manufacturer focusing on diseases of the digestive system and metabolic system


Share to

Recently, Hangzhou Tangji Medical Technology Co., Ltd. (hereinafter referred to as "Tangji Medical") announced that it has completed tens of millions of financing in the first quarter of 2021. This financing was led by BV Baidu Ventures, followed by investors such as Langmafeng Ventures and Top Heart Capital. According to Zuo Yuxing, founder and CEO of Tangji Medical, the funds raised this time will provide a strong support for Tangji Medical's ongoing clinical research and production line construction of the "gastric bypass stent system".

Founded in 2016, Tangji Medical is a high-tech enterprise focusing on the research and development of new treatment methods for metabolic diseases such as obesity, diabetes, and fatty liver. At present, it is commited to working on noninvasive implants for metabolic diseases--Innovative R&D and clinical research of the "gastric bypass stent system".

It is reported that Tangji Medical, as a firm implementer of China’s innovative medical technology, has developed a gastric bypass stent system that can be placed under a gastroscope, is basically non-invasive and can be removed. It is easier to operate than traditional weight loss surgery with advantages such as damage-free to the human body structure and less damage to the subject. The principle of the effect of the gastric bypass stent system is: a cannula is placed in the duodenum and upper jejunum through a gastroscope to isolate the chyme. After placement, the food from the stomach is passed through the cannula cavity, and the bile and pancreatic juice are isolated. Outside the cannula, the bile pancreatic juice and food "shunt", blocking the digestion and absorption of food. Clinically, it can be used to help control obesity, diabetes, non-alcoholic fatty liver and other metabolic diseases, with good application prospects.

Tangji medical gastric bypass stent system has obtained more than 20 domestic and foreign patents in total, of which 4 invention patents are under review in the United States, the European Union, Japan, Russia and other countries. In August 2020, the stent system has been reviewed by the Medical Device Technology Review Center of the State Drug Administration and entered the special review process for innovative medical devices. At present, the clinical research on the treatment of obesity with the Tangji gastric bypass stent system implantation has also been carried out in cooperation with many top three hospitals in Beijing, Nanjing, Tianjin, Xi'an, Shenyang, Harbin, Hohhot and other places, and has achieved good results---Three months after the implantation of the stent system, the additional weight loss percentage (EWL%) was 25%-76%; the glycosylated hemoglobin value decreased by 1.5, and liver fibrosis was controlled.

Tangji Medical Gastric Bypass Stent System

In 2021, Zhang Shutian, Dean of Beijing Friendship Hospital affiliated to Capital Medical University, will be at the "National Endoscopic Minimally Invasive Weight Loss Academic Conference" hosted by the National Research Center for Digestive Diseases Clinical Medicine, China Medical Quality Management Association and other institutions. "The current endoscopic weight loss treatment program in China is almost blank. The innovative technology of the gastric bypass stent system has rarely appeared in the country. This is exactly what we need. If the stent system can be comprehensive in China in the future The application will help patients with metabolic diseases relieve their pain, regain their health and happiness, and open a new era of endoscopic interventional treatment of metabolic diseases."

At the “Report on Nutrition and Chronic Disease Status of Chinese Residents (2020)” held by the State Information Office, Zhao Wenhua, chief expert on nutrition at the Chinese Center for Disease Control and Prevention, stated that more than 50% of adult residents in China are overweight and obese, and children and adolescents aged 6-17 Nearly 20% and 10% of children under the age of 6 can be used to describe the current form of overweight and obesity in the current population with a rapid rise in overweight and obesity, a high prevalence level, and the impact of the entire population. According to the OECD report, in OECD countries, the cost of treating diseases caused by overweight accounts for about 8.4% of total health expenditure. Under such a general environment, the various health problems caused by obesity cannot be underestimated, and China urgently needs to seek more advanced and efficient medical methods for controlling obesity. In order to actively respond to the Party Central Committee’s "Healthy China 2030" plan, Mr. Zuo Yuxing, the founder and CEO of Tangji Medical, said: “Tangji has a leading medical technology team, strong intellectual property rights and determination to provide excellent medical solutions. The medical field of metabolic diseases such as obesity, diabetes and fatty liver is an important direction for us. Tangji will not forget the original intention and drive the research and development of new technologies and new projects with innovation to benefit the majority of patients. "

An Feng, vice president of investment of BV Baidu Ventures, the lead investor in this round, explained that: "optimistic that Tangji Medical’s flagship product can replace traditional gastric bypass surgery and is superior to other implantable weight loss products currently on the market. It is expected to be able to simultaneously Achieve non-invasive weight loss, lower blood sugar levels in diabetic patients, and improve the symptoms of non-alcoholic fatty liver patients. While achieving the above medical effects, it avoids short-term side effects and long-term complications caused by surgery and other substituted products. In the future, in the medical field, it can uniquely improve the treatment effect of diabetes and obesity patients. In the field of medical beauty and health management, It can also bring obvious value to consumers in need. It is believed that Tangji will seize the opportunity at the golden time when the light medical beauty track is rapidly heating up, and lead the new consumption trend of light medical beauty, light health, and BV will continue to pay attention to this direction to help the next generation of healthy life!"

Star Project

Big Data Service Platform Provider for Tumor Gene

4D Millimeter Wave Radar

three-electric monitoring technology and service provider for new energy vehicle

Using this website means that you agree to our use of cookies. We use cookies to provide you with a good experience and help our website operate effectively.